Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC

被引：0

作者：

Waterhouse, D. M. ^{[1
]}

Rothschild, S. ^{[2
]}

Dooms, C. ^{[3
]}

Mennecier, B. ^{[4
]}

Bozorgmehr, F. ^{[5
]}

Majem, M. ^{[6
]}

van den Heuvel, M. ^{[7
]}

Linardou, H. ^{[8
,9
]}

Chul-Cho, B. ^{[10
]}

Roberts-Thomson, R. ^{[11
]}

Okamoto, I. ^{[12
]}

Blais, N. ^{[13
]}

Schvartsman, G. ^{[14
]}

Holmskov, K. ^{[15
]}

Chmielewska, I. ^{[16
]}

Forster, M. ^{[17
]}

Stollenwerk, B. ^{[18
]}

Obiozor, C. C. ^{[19
]}

Wang, Y. ^{[19
]}

Novello, S. ^{[20
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Univ Basel, Ctr Comprehens Canc, Med Oncol, Basel, Switzerland

[3] Univ Hosp, Dept Resp Dis, Leuven, Belgium

[4] Univ Hosp Strasbourg, Pulmonol Unit, Strasbourg, France

[5] Univ Hosp Heidelberg, Dept Thorac Oncol, Thoraxklin, Heidelberg, Germany

[6] Hosp Santa Creu & Sant Pau, Med Oncol, Serv Oncol Med, Barcelona, Spain

[7] Radboud Univ Nijmegen, Dept Resp Dis, Med Ctr, Nijmegen, Netherlands

[8] Metropolitan Hosp, Oncol Dept 4, Athens, Greece

[9] Metropolitan Hosp, Comprehens Clin Trials Ctr, Athens, Greece

[10] Yonsei Univ, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr,Coll Med, Seoul, South Korea

[11] Queen Elizabeth Hosp, Dept Med Oncol, Woodville, SA, Australia

[12] Kyushu Univ Hosp, Fukuoka, Japan

[13] Ctr Hosp Univ Montreal, Dept Med, Montreal, PQ, Canada

[14] Hosp Israelita Albert Einstein, Ctr Oncol & Hematol Einstein Famila Dayan Daycova, Sao Paulo, Brazil

[15] Odense Univ Hosp, Dept Oncol, Odense, Denmark

[16] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, Lublin, Poland

[17] UCL, Canc Inst, London, England

[18] Amgen Europe GmbH, Rotkreuz, Switzerland

[19] Amgen Inc, Thousand Oaks, CA USA

[20] Univ Torino, Dept Oncol, San Luigi Hosp, Turin, Italy

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S37 / S38

页数：2

共 50 条

[1] Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation
Waterhouse, David M.
Rothschild, Sacha
Dooms, Christophe
Mennecier, Bertrand
Bozorgmehr, Farastuk
Majem, Margarita
Heuvel, Michel H. van den
Linardou, Helena
Cho, Byoung Chul
Roberts-Thomson, Rachel
Tanaka, Kentaro
Blais, Normand
Schvartsman, Gustavo
Hansen, Karin Holmskov
Chmielewska, Izabela
Forster, Martin D.
Giannopoulou, Christina
Stollenwerk, Bjorn
Obiozor, Cynthia C.
Wang, Yang
Novello, Silvia
LUNG CANCER, 2024, 196
[2] CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC
Clarke, J. M.
Felip, E.
Li, B. T.
Ruffinelli, J. C.
Garrido, P.
Zugazagoitia, J.
Goldberg, S. B.
Ramalingam, S. S.
Victoria, I.
Puri, S.
Gandara, D. R.
Varrieur, T.
Edmonds, S.
Palmer, K.
Snyder, W.
Govindan, R.
Rybkin, I.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S118 - S119
[3] Biomarker subgroup analyses of the Phase III study CodeBreaK 200 comparing sotorasib to docetaxel in pretreated patients with KRAS G12C-mutated non-small cell lung cancer
Schuler, M.
de, langen A. J.
Paz-Ares, L.
Mountzios, G.
Curioni-Fontecedro, A.
Couraud, S.
Jansenns, A.
Rocco, D.
Ohashi, K.
Vincent, M.
Kang, J. -H.
Schvartsman, G.
Lindsay, C.
O'Byrne, O.
Dziadziuszko, R.
Andersen, J. L.
Hindoyan, A.
Wilmanski, T.
Wang, Y.
Skoulidis, F.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 148 - 149
[4] Impact of Sotorasib and Adagrasib in KRAS G12C-Mutated NSCLC
Patel, Sandip P.
ONCOLOGY-NEW YORK, 2023, 37 (12): : 479 - 479
[5] Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC)
Skoulidis, Ferdinandos
De langen, Adrianus
Paz-Ares, Luis G.
Mountzios, Giannis Socrates
Curioni-Fontecedro, Alessandra
Couraud, Sebastien
Janssens, Annelies
Rocco, Danilo
Ohashi, Kadoaki
Vincent, Mark David
Kang, Jin-Hyoung
Schvartsman, Gustavo
Lindsay, Colin R.
O'Byrne, Kenneth John
Dziadziuszko, Rafal
Andersen, Jon A. Lykkegaard
Hindoyan, Antreas
Wilmanski, Tomasz
Wang, Yang
Schuler, Martin H.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC).
Spira, Alexander I.
Wilson, Frederick Hugh
Shapiro, Geoffrey
Dooms, Christophe
Curioni-Fontecedro, Alessandra
Esaki, Taito
Barlesi, Fabrice
Cocks, Kim
Trigg, Andrew
Stevinson, Kendall
Matsuda, Tara
Tran, Qui
Gray, Jhanelle Elaine
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials
Skoulidis, F.
Li, B. T.
Hochmair, M. J.
Govindan, R.
Vincent, M.
Van der Wekken, A. J.
Reguart Aransay, N.
O'Byrne, K. J.
Girard, N.
Griesinger, F.
Nishio, M.
Hafliger, S.
Lindsay, C.
Reinmuth, N.
Paulus, A.
Papakotoulas, P.
Obiozor, C.
Nduka, C.
Wang, Y.
De Langen, A. J.
ANNALS OF ONCOLOGY, 2024, 35 : S830 - S831
[8] Assessing the safety profile of sotorasib in KRAS G12C-mutated advanced NSCLC
Reactions Weekly, 2025, 2045 (1) : 6 - 6
[9] FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
Nakajima, Erica C.
Drezner, Nicole
Li, Xiaoxue
Mishra-Kalyani, Pallavi S.
Liu, Yajun
Zhao, Hong
Bi, Youwei
Liu, Jiang
Rahman, Atiqur
Wearne, Emily
Ojofeitimi, Idara
Hotaki, Lauren Tesh
Spillman, Dianne
Pazdur, Richard
Beaver, Julia A.
Singh, Harpreet
CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1482 - 1486
[10] Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study
Kuboki, Y.
Pietrantonio, F.
Salvatore, L.
Esaki, T.
Modest, D. P.
Paez, D.
Taieb, J.
Ruiz, E.
Kim, T. W.
Meriggi, F. A.
Cunningham, D.
Yeh, K-H.
Chan, E.
Chao, J.
Strydom, N.
Saportas, Y.
Tran, Q.
Cremolini, C.
Fakih, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1504 - S1505

← 1 2 3 4 5 →